1. Search Result
Search Result
Results for "

matrigel

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

10

MCE Kits

1

Inhibitory Antibodies

1

Natural
Products

1

Recombinant Proteins

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103444

    MMP Cancer
    ARP-100 is a potent and selective matrix metalloproteinase MMP-2 inhibitor (IC50=12 nM). ARP-100 interacts with S1' pocket of MMP-2 and shows anti-invasive properties in an in vitro model of invasion on matrigel. ARP-100 shows the less inhibitory activity towards MMP-1 (>50 μM), MMP-3 (4.5 μM), MMP-7 (>50 μM), and MMP-9 (0.2 μM) .
    ARP-100
  • HY-B1074

    Etamsylate

    Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .
    Ethamsylate
  • HY-15478
    WZ811
    3 Publications Verification

    CXCR Endocrinology Cancer
    WZ811 is an orally active, highly potent competitive antagonist of CXCR4. WZ811 efficiently inhibits CXCR4/SDF-1 (or CXCL12)-mediated modulation of cAMP levels (EC50=1.2 nM) and SDF-1 induced Matrigel invasion in cells (EC50=5.2 nM) .
    WZ811
  • HY-128341

    ERK Cardiovascular Disease Cancer
    ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain. ERK5-IN-2 suppresses both tumor xenograft growth and basic fibroblast growth factor (bFGF) driven Matrigel plug angiogenesis .
    ERK5-IN-2
  • HY-149394
    PRDX1-IN-1
    1 Publications Verification

    Apoptosis ROS Kinase Cancer
    PRDX1-IN-1 is a selective inhibtor of PRDX1 with an IC50 value of 0.164 μM. PRDX1-IN-1 can be used in researches related to cancer.PRDX1-IN-1 promots intracellular ROS accumulation, and inhibits the proliferation, invasion and migration of cancer cells besides inducing apoptosis. PRDX1-IN-1 could be used in cancer research .
    PRDX1-IN-1
  • HY-N1419

    AMPK Akt ERK p38 MAPK NF-κB Nuclear Factor of activated T Cells (NFAT) JNK Cardiovascular Disease Metabolic Disease
    Vaccarin is an orally active flavonoid glycoside with multiple biological functions. Vaccarin promotes neovascularization by activating AKT and ERK. Vaccarin activates the AMPK signaling pathway to improve insulin resistance and steatosis. Vaccarin is a MAPK, NF-κB, and NFAT inhibitor, effectively blocking RANKL-induced osteoclastogenesis .
    Vaccarin
  • HY-103444R

    MMP Cancer
    ARP-100 (Standard) is the analytical standard of ARP-100. This product is intended for research and analytical applications. ARP-100 is a potent and selective matrix metalloproteinase MMP-2 inhibitor (IC50=12 nM). ARP-100 interacts with S1' pocket of MMP-2 and shows anti-invasive properties in an in vitro model of invasion on matrigel. ARP-100 shows the less inhibitory activity towards MMP-1 (>50 μM), MMP-3 (4.5 μM), MMP-7 (>50 μM), and MMP-9 (0.2 μM) .
    ARP-100 (Standard)
  • HY-B1074R

    Etamsylate (Standard)

    Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Ethamsylate (Standard) is the analytical standard of Ethamsylate. This product is intended for research and analytical applications. Ethamsylate (Etamsylate) is an orally active anti-hemorrhagic compound. Ethamsylate inhibits biosynthesis and action of prostaglandins. Ethamsylate has the potential to maintain early hemostasis as well as restores capillary resistance. Ethamsylate acts as an antiangiogenic factor, inhibiting wound healing and matrigel tubulogenesis. .
    Ethamsylate (Standard)
  • HY-P991310

    LT3015; LT-3000

    LPL Receptor Neurological Disease Cancer
    Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Lpathomab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: